Hvis der kommer persisterende, klinisk relevante stigninger af transaminaserne, bør det overvejes at reducere dosis eller stoppe behandlingen.
However, in the event of persistent clinically relevant elevation of transaminase levels, reduction of the dose or discontinuation of treatment should be considered.